Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Jörg D. Hoheisel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1583-5049; OpenAlex author ID A5017815858. Sources: OpenAlex.

Their work

Papers
32 (first author 1, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
107
Papers, trials and grants by year

2011: 3 papers · 2012: 3 papers · 2013: 4 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 32

  1. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  2. Blood-based prediction and early detection of pancreatic cancer recurrence after tumor resection Co-author DOI 10.20892/j.issn.2095-3941.2025.0495↗
  3. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Co-author DOI 10.1002/1878-0261.13747↗
  4. Phoenix dactylifera L. (date palm) fruit extracts and fractions exhibit anti-proliferative activity against human pancreatic cancer cell lines. First author DOI 10.1016/j.heliyon.2025.e42274↗
  5. A systemic look at pancreatic cancer patients: Predicting metastasis by studying the liver. Last author DOI 10.1038/s41392-024-01964-4↗
  6. Genome-Wide CRISPR Screen Identifies Genes Involved in Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16213684↗
  7. DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma. Last author DOI 10.1136/gutjnl-2023-330155↗
  8. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40170-022-00298-5↗
  9. Blood biomarkers for differential diagnosis and early detection of pancreatic cancer. Last author DOI 10.1016/j.ctrv.2021.102193↗
  10. Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2021.07.23.452145↗
  11. Promoter Hypermethylation Promotes the Binding of Transcription Factor NFATc1, Triggering Oncogenic Gene Activation in Pancreatic Cancer. Last author DOI 10.3390/cancers13184569↗
  12. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis. Co-author DOI 10.1002/1878-0261.12684↗
  13. Antifibrotic and tumor microenvironment modulating effect of date palm fruit (Phoenix dactylifera L.) extracts in pancreatic cancer. Co-author DOI 10.1016/j.biopha.2019.109522↗
  14. Novel Autoantibody Signatures in Sera of Patients with Pancreatic Cancer, Chronic Pancreatitis and Autoimmune Pancreatitis: A Protein Microarray Profiling Appr… Co-author DOI 10.3390/ijms21072403↗
  15. The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer. Co-author DOI 10.1080/14728222.2019.1606904↗
  16. Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. Last author DOI 10.1002/ijc.31087↗
  17. Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.14449↗
  18. The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators. Co-author DOI 10.18632/oncotarget.19882↗
  19. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Last author DOI 10.1053/j.gastro.2016.08.040↗
  20. Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression. Last author DOI 10.1158/0008-5472.can-15-0390↗
  21. Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. Co-author DOI 10.15252/emmm.201404837↗
  22. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. Co-author DOI 10.1038/onc.2013.312↗
  23. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Co-author DOI 10.1158/1055-9965.epi-12-1182↗
  24. Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. Co-author DOI 10.1242/jcs.124768↗
  25. In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts. Co-author DOI 10.1371/journal.pone.0074555↗
  26. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.3892/or.2013.2285↗
  27. Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines. Last author DOI 10.1016/j.jprot.2012.04.042↗
  28. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. Last author DOI 10.1371/journal.pone.0034151↗
  29. Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system. Last author DOI 10.1371/journal.pone.0048503↗
  30. Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells. Last author DOI 10.1016/j.ejphar.2010.10.026↗
  31. Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Last author DOI 10.1111/j.1476-5381.2010.01125.x↗
  32. Pancreatic cancer susceptibility loci and their role in survival. Co-author DOI 10.1371/journal.pone.0027921↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrea S. Bauer · 18 shared papers, 2011–2026 · strength 1.50
  2. Mohamed Saiel Saeed Alhamdani · 7 shared papers, 2012–2026 · strength 1.19
  3. Thilo Hackert · 10 shared papers, 2016–2026 · strength 1.07
  4. Markus Wolfgang Büchler · 11 shared papers, 2011–2026 · strength 0.97
  5. Nathalia A. Giese · 13 shared papers, 2011–2023 · strength 0.88
  6. Fawaz N. Al-Shaheri · 3 shared papers, 2021–2026 · strength 0.56
  7. Younis Baqi · 2 shared papers, 2020–2025 · strength 0.53
  8. Reem A. Al Alawi · 2 shared papers, 2020–2025 · strength 0.53
  9. Oliver Strobel · 8 shared papers, 2015–2020 · strength 0.52
  10. Yenan Wu · 3 shared papers, 2020–2023 · strength 0.40
  11. Phyllis F. Cheung · 3 shared papers, 2021–2025 · strength 0.40
  12. Marija Trajkovic‐Arsic · 3 shared papers, 2021–2025 · strength 0.40
  13. Jens Thomas Siveke · 3 shared papers, 2021–2025 · strength 0.40
  14. Smiths Lueong · 3 shared papers, 2021–2025 · strength 0.40
  15. Susanne Roth · 1 shared paper, 2024 · strength 0.36
  16. Christoph W. Michalski · 1 shared paper, 2024 · strength 0.36
  17. Michael Boettcher · 3 shared papers, 2012–2024 · strength 0.30
  18. Mehdi Manoochehri · 2 shared papers, 2020–2023 · strength 0.27
  19. John P. Neoptolemos · 7 shared papers, 2011–2018 · strength 0.25
  20. Miriam Schenk · 1 shared paper, 2026 · strength 0.25
  21. Ulrike Heger · 1 shared paper, 2026 · strength 0.25
  22. William Greenhalf · 6 shared papers, 2011–2018 · strength 0.23
  23. Eithne Costello · 6 shared papers, 2011–2018 · strength 0.23
  24. Pouria Jandaghi · 3 shared papers, 2016–2019 · strength 0.23
  25. Risky Oktriani · 1 shared paper, 2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.